{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:22:11Z","timestamp":1793110931903,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1097\/maj.0b013e31814a586a","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T14:16:15Z","timestamp":1236262575000},"page":"126-136","source":"Crossref","is-referenced-by-count":118,"title":["Update on Rifampin and Rifabutin Drug Interactions"],"prefix":"10.1016","volume":"335","author":[{"given":"Anne M.","family":"Baciewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cary R.","family":"Chrisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher K.","family":"Finch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy H.","family":"Self","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/MAJ.0b013e31814a586a_bb0005","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1001\/archinte.144.8.1667","article-title":"Rifampin drug interactions","volume":"144","author":"Baciewicz","year":"1984","journal-title":"Arch Intern Med"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0010","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/archinte.1987.00370030169033","article-title":"Update on rifampin drug interactions","volume":"147","author":"Baciewicz","year":"1987","journal-title":"Arch Intern Med"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0015","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/archinte.1992.00400160029007","article-title":"Update on rifampin drug interactions II","volume":"152","author":"Borcherding","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0020","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1001\/archinte.1997.00440420085007","article-title":"Update on rifampin drug interactions III","volume":"157","author":"Strayhorn","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0025","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archinte.162.9.985","article-title":"Rifampin and rifabutin drug interactions","volume":"162","author":"Finch","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0092-8674(00)80900-9","article-title":"An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway","volume":"92","author":"Kliewer","year":"1998","journal-title":"Cell"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0035","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1124\/jpet.102.043026","article-title":"Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-, mediated pregnane X receptor activation","volume":"304","author":"Tirona","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0040","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clpt.2005.02.006","article-title":"Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers","volume":"77","author":"Chung","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0045","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1592\/phco.22.5.387.33190","article-title":"Intravenous cyclosporine-rifampin interaction in a pediatric bone marrow transplant recipient (letter)","volume":"22","author":"Zelunka","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0050","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1345\/aph.1A384","article-title":"Effect of rifampin on apparent clearance of everolimus","volume":"36","author":"Kovarik","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0055","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/j.transproceed.2003.08.019","article-title":"Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: a case report","volume":"35","author":"Bhaloo","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0060","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.clpt.2005.03.004","article-title":"Drug interaction between Mycophenolate mofentil and rifampin: possible induction of uridine diphosphate-glucuronosyltransferase","volume":"78","author":"Kuypers","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0065","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1086\/376648","article-title":"Rifamycin treatment of tuberculosis in a patient receiving atenolol: less interaction with rifabutin than with rifampin (letter)","volume":"37","author":"Goldberg","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"10.1097\/MAJ.0b013e31814a586a_bb0070","first-page":"28","article-title":"Pharmacokinetics of beta-adrenoceptor blocking agents: clinical significance of hepatic and\/or renal clearance","volume":"8","author":"Borchard","year":"1990","journal-title":"Clin Physiol Biochem"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0075","first-page":"1183","article-title":"Metabolic actions of a single atenolol and metoprolol dose","volume":"44","author":"Kulcsar-Gergely","year":"1994","journal-title":"Arzneimittelforschung"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0080","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.0306-5251.2001.01545.x","article-title":"The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects","volume":"53","author":"Saima","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0085","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clpt.2005.04.007","article-title":"Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites","volume":"78","author":"Backman","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0090","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1046\/j.1365-2125.2003.01972.x","article-title":"Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects","volume":"57","author":"Kyrklund","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0095","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.2337\/diacare.23.8.1204","article-title":"Interaction of gliclazide and rifampicin (letter)","volume":"23","author":"Kihara","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0100","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0009-9236(03)00221-2","article-title":"Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide","volume":"74","author":"Park","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0105","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1365-2125.2000.00295.x","article-title":"Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride","volume":"50","author":"Neimi","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0110","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/0091270003253704","article-title":"Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide","volume":"43","author":"Hatorp","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0115","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1067\/mcp.2000.111183","article-title":"Rifampin decreases the plasma concentrations and effects of repaglinide","volume":"68","author":"Niemi","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0120","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00228-004-0746-z","article-title":"Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide","volume":"60","author":"Bidstrup","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0125","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2125.2003.01884.x","article-title":"Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects","volume":"56","author":"Niemi","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.clpt.2003.10.003","article-title":"Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects","volume":"75","author":"Park","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0135","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.clpt.2004.05.001","article-title":"Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P4502C8 substrate rosiglitazone","volume":"76","author":"Niemi","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0140","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-2125.2005.02515.x","article-title":"Effect of rifampicin on the pharmacokinetics of pioglitazone","volume":"61","author":"Jaakkola","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0145","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1345\/aph.1G370","article-title":"Rifampin reduces the analgesic effect of transdermal fentanyl (letter)","volume":"39","author":"Takane","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0150","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/00000542-200409000-00022","article-title":"Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate","volume":"101","author":"Kharasch","year":"2004","journal-title":"Anesthesiology"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0155","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1515\/DMDI.2003.19.4.287","article-title":"Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers","volume":"19","author":"Jayasagar","year":"2003","journal-title":"Drug Metabol Drug Interact"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0160","series-title":"Vioxx package insert","year":"2003"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0165","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1111\/j.1572-0241.2001.03734.x","article-title":"Hepatic failure and encephalopathy attributed to an interaction between acetaminophen and rifampicin (letter)","volume":"98","author":"Stephenson","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0170","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1177\/0091270003259220","article-title":"Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide","volume":"43","author":"Boyd","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0175","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1128\/AAC.49.2.680-684.2005","article-title":"Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers","volume":"49","author":"Droste","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0180","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1086\/345532","article-title":"A regimen containing rifabutin for the treatment of tuberculosis in patients intolerant to rifampin","volume":"36","author":"Tattevin","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0185","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(98)11467-8","article-title":"Acquired rifamycin monoresistance in patients with HIV related tuberculosis treated with once-weekly rifapentine and isoniazid: Tuberculosis Trials Consortium","volume":"353","author":"Vernon","year":"1999","journal-title":"Lancet"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0190","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/429321","article-title":"Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis","volume":"40","author":"Weiner","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0195","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1128\/AAC.48.5.1553-1560.2004","article-title":"Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers","volume":"48","author":"la Porte","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0200","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1128\/AAC.48.11.4473-4475.2004","article-title":"Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease","volume":"48","author":"Gurumurthy","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0205","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/01.qai.0000182629.74336.4d","article-title":"Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study)","volume":"40","author":"Ribera","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0210","series-title":"Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents.","article-title":"(DHHS) Panel on Clinical Practices for Treatment of HIV Infection","year":"2006"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0215","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1097\/01.aids.0000131390.83844.5c","article-title":"Failure of treatment of tuberculous adenitis due to an unexpected drug interaction with rifabutin and efavirenz","volume":"18","author":"Edelstein","year":"2004","journal-title":"AIDS"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0220","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1086\/343047","article-title":"Drug-drug interactions in inmates treated for human immunodeficiency virus and mycobacterium tuberculosis infection or disease: an Institutional Tuberculosis Outbreak","volume":"35","author":"Spradling","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0225","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2125.2005.02536.x","article-title":"Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism","volume":"61","author":"Burger","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0230","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.aids.0000196181.18916.9b","article-title":"Efavirenz 600mg\/day versus efavirenz 800mg\/day in HIV-infected patients with tuberculosis receiving rifampicin: 48weeks results","volume":"20","author":"Manosuthi","year":"2006","journal-title":"AIDS"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0235","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/jac\/dkl357","article-title":"Efavirenz trough levels are not associated with virological failure throughout therapy with 800mg daily and a rifampicin-containing antituberculosis regimen","volume":"58","author":"Lopez-Cortes","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0240","author":"Sheehan","year":"2005"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0245","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1086\/510078","article-title":"Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis","volume":"44","author":"Manosuthi","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0250","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/01.qai.0000214808.75594.73","article-title":"Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration","volume":"41","author":"Ramachandran","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0255","first-page":"124","article-title":"Concentration of clarithromycin and 14-R-hydroxy-clarithromycin in plasma of patients with Mycobacterium avium complex infection, before and after the addition of rifampicin","volume":"57","author":"Yamamoto","year":"2004","journal-title":"Jpn J Antibiot"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0260","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1128\/AAC.45.11.3238-3241.2001","article-title":"Rifampin reduces concentrations of trimethoprim and sulfamethoxazole in serum in human immunodeficiency virus-infected patients","volume":"45","author":"Ribera","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0265","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1086\/313515","article-title":"Comparison of high and low doses of trimethoprim-sulfamethoxazole for primary prevention of toxoplasmic encephalitis in human immunodeficiency virus-infected patients","volume":"29","author":"Ribera","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0270","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1128\/AAC.48.11.4306-4314.2004","article-title":"Potential for interactions between caspofungin and nelfinavir or rifampin","volume":"48","author":"Stone","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0275","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2165\/00003088-200443110-00003","article-title":"Effect of rifampicin on the pharmacokinetics of fluconazole in patients with AIDS","volume":"43","author":"Ayudhya","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0280","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1089\/108729101753205667","article-title":"Possible clinically significant interaction of itraconazole plus rifampin","volume":"15","author":"Todd","year":"2001","journal-title":"AIDS Patient Care STDS"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0285","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1592\/phco.25.3.435.61591","article-title":"Exacerbation of panic disorder with rifampin therapy in a patient receiving citalopram","volume":"25","author":"Kukoyi","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0290","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1128\/AAC.47.5.1509-1513.2003","article-title":"Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria","volume":"47","author":"Pukrittayakamee","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0295","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1211\/0022357001777243","article-title":"Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers","volume":"52","author":"Ridtitid","year":"2000","journal-title":"J Pharm Pharmacol"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0300","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1067\/mcp.2002.129319","article-title":"Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers","volume":"72","author":"Ridtitid","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0305","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S0009-9236(01)29243-1","article-title":"Effect of rifampin and tobacco smoking on the pharmacokinetics of ropivacaine","volume":"70","author":"Jokinen","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0310","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00280-003-0722-9","article-title":"Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects","volume":"53","author":"Bolton","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0315","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2165\/00003088-200544100-00005","article-title":"Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol","volume":"44","author":"Swaisland","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0320","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00045391-200105000-00003","article-title":"Rifampicin pharmacokinetics with and without ciprofloxacin","volume":"8","author":"Orisakwe","year":"2001","journal-title":"Am J Ther"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0325","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00045391-200405000-00004","article-title":"Urinary excretion of rifampicin in the presence of ciprofloxacin","volume":"11","author":"Orisakwe","year":"2004","journal-title":"Am J Ther"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0330","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/01.mjt.0000117523.18923.4a","article-title":"Some plasma and saliva pharmacokinetics parameters of rifampicin in the presence of pefloxacin","volume":"11","author":"Orisakwe","year":"2004","journal-title":"Am J Ther"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0335","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00045391-200401000-00006","article-title":"Effect of pefloxacin on the urinary excretion of rifampicin","volume":"11","author":"Orisakwe","year":"2004","journal-title":"Am J Ther"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0340","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s10147-004-0394-4","article-title":"Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer","volume":"9","author":"Yonemori","year":"2004","journal-title":"Int J Clin Oncol"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0345","first-page":"587","article-title":"The clearance of theophyllines increased during the initial period of tuberculosis treatment","volume":"7","author":"Ahn","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1097\/MAJ.0b013e31814a586a_bb0350","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1067\/mcp.2002.128387","article-title":"Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin","volume":"72","author":"Paine","year":"2002","journal-title":"Clin Pharmacol Ther"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915323727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915323727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T18:41:46Z","timestamp":1633200106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915323727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S0002962915323727"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e31814a586a","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}